Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Apr 18;2007(2):CD004654.
doi: 10.1002/14651858.CD004654.pub2.

Meglitinide analogues for type 2 diabetes mellitus

C Black  1 , P Donnelly, L McIntyre, P L Royle, J P Shepherd, S Thomas
Affiliations

Meglitinide analogues for type 2 diabetes mellitus

C Black et al. Cochrane Database Syst Rev. .

Abstract

Background: In type 2 diabetes mellitus, impairment of insulin secretion is an important component of the disease. Meglitinide analogues are a class of oral hypoglycaemic agents that increase insulin secretion, in particular, during the early phase of insulin release.

Objectives: The aim of this review was to assess the effects of meglitinide analogues in patients with type 2 diabetes mellitus.

Search strategy: We searched several databases including The Cochrane Library, MEDLINE and EMBASE. We also contacted manufacturers and searched ongoing trials databases, and the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) websites.

Selection criteria: We included randomised controlled, parallel or cross-over trials comparing at least 10 weeks of treatment with meglitinide analogues to placebo, head-to-head, metformin or in combination with insulin.

Data collection and analysis: Two authors independently extracted data and assessed trial quality.

Main results: Fifteen trials involving 3781 participants were included. No studies reported the effect of meglitinides on mortality or morbidity. In the eleven studies comparing meglitinides to placebo, both repaglinide and nateglinide resulted in a reductions in glycosylated haemoglobin (0.1% to 2.1% reduction in HbA1c for repaglinide; 0.2% to 0.6% for nateglinide). Only two trials compared repaglinide to nateglinide (342 participants), with greater reduction in glycosylated haemoglobin in those receiving repaglinide. Repaglinide (248 participants in three trials) had a similar degree of effect in reducing glycosylated haemoglobin as metformin. Nateglinide had a similar or slightly less marked effect on glycosylated haemoglobin than metformin (one study, 355 participants). Weight gain was generally greater in those treated with meglitinides compared with metformin (up to three kg in three months). Diarrhoea occurred less frequently and hypoglycaemia occurred more frequently but rarely severely enough as to require assistance.

Authors' conclusions: Meglitinides may offer an alternative oral hypoglycaemic agent of similar potency to metformin, and may be indicated where side effects of metformin are intolerable or where metformin is contraindicated. However, there is no evidence available to indicate what effect meglitinides will have on important long-term outcomes, particularly mortality.

PubMed Disclaimer

Conflict of interest statement

None known.

Comment in

References

References to studies included in this review

Bengel 2005 {published data only}
    1. Bengel FM, Abletshauser C, Neverve J, Schnell O, Nekolla SG, Standl E, Schwaiger M. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus‐‐a randomized study using positron emission tomography. Diabetic Medicine 2005;22(2):158‐63. - PubMed
Chuang 1999 {published data only}
    1. Chuang L, Tai T, Juang JH, Chiang YD, Ki K, Jorgensen LN, Yeo LP. Effect of a prandial glucose regulator (NovoNorm) at two doses (0.5 mg and 2 mg) on glycemic control in type 2 diabetes in Taiwan. JAMA Southeast Asia 1999;15(1):22‐5.
Derosa 2003 {published data only}
    1. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice 2003;60(3):161‐9. - PubMed
Furlong 2002 {published data only}
    1. Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002;25(10):1685‐90. - PubMed
Goldberg 1998 {published data only}
    1. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, et al. A randomized placebo‐controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21(11):1897‐903. - PubMed
Hanefeld 2000 {published data only}
    1. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short‐acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23(2):202‐7. - PubMed
Horton 2000 {published data only}
    1. Foley JE, Gatlin M, Dunn FL, Horton ES. Both nateglinide and metformin sustain HbA(1c) lowering over 52 weeks in drug‐naive type 2 diabetes patients. Diabetologia 2003;44(Suppl 1):826.
    1. Horton E, James F, Shen S, Baron M. Initial combination therapy (CT) with nateglinide and metformin is safe and effective. Diabetes 2003;52(Suppl 1):A448.
    1. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23(11):1660‐5. - PubMed
Jovanovic 2000 {published data only}
    1. Jovanovic L, Dailey G, III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24‐week, fixed‐dose efficacy and safety study. Journal of Clinical Pharmacology 2000;40(1):49‐57. - PubMed
Marre 2002 {published data only}
    1. Marre A, Gaal L, Usadel KH, Ball A, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obesity & Metabolism 2002;4(3):177‐86. - PubMed
Moses 1999 {published data only}
    1. Moses R. Repaglinide in combination therapy with metformin in Type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes 1999;107(Suppl 4):S136‐9. - PubMed
    1. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22(1):119‐24. - PubMed
Moses 2001 {published data only}
    1. Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy‐naive Type 2 diabetes: A placebo‐ controlled, multicentre study. Quality of Life Research 2003;12(4):413‐25. - PubMed
    1. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal‐related dosing with repaglinide facilitates glycemic control in therapy‐naive type 2 diabetes. Diabetes Care 2001;24(1):11‐5. - PubMed
Raskin 2003 {published data only}
    1. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, et al. Efficacy and Safety of Combination Therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26(7):2063‐8. - PubMed
Rosenstock 2004 {published data only}
    1. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27(6):1265‐70. - PubMed
Saloranta 2002 {published data only}
    1. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. Journal of Clinical Endocrinology & Metabolism 2002;87(9):4171‐6. - PubMed
Van Gaal 2001 {published data only}
    1. Gaal LF, Acker KL, Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea‐naive type 2 diabetes. Diabetes Research & Clinical Practice 2001;53(3):141‐8. - PubMed

References to studies excluded from this review

Baron 2002 {published data only}
    1. Baron MA, Mager RR, Vyas KH, Das Purkayastha D. Nateglinide (Starlix((R)) effectively lowers HbA(1c), through reductions in post prandial glucose in subjects with type 2 diabetes mellitus. Diabetes 2002;51(Suppl. 2):376.
Barone 2004 {published data only}
    1. Barone M, Aiello A, Allochis G, Borzi V, Cannata E, Caronna S, et al. Repaglinide‐metformin combination in the treatment of type 2 diabetes: Comparison between three different combination regimens. Diabetologia 2004;47(Suppl 1):A15.
Chen 2002 {published data only}
    1. Chen YM, Zeng LY, Zhang GC, Jiang BQ, Qian XX. Clinical effects of repaglinide on type 2 diabetes mellitus. Chinese Journal of New Drugs and Clinical Remedies 2002;21(8):498‐500.
Cozma 2002 {published data only}
    1. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002;25(8):1271‐6. - PubMed
Damsbo 1999 {published data only}
    1. Damsbo P, Marbury TC, Hatorp V, Clauson P, Muller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Research & Clinical Practice Supplement 1999;45(1):31‐9. - PubMed
De Luis 2001 {published data only}
    1. Luis DA, Aller R, Cuellar L, Terroba C, Ovalle H, Izaola O, Romero E. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24(10):1844‐5. - PubMed
Foley 2001 {published data only}
    1. Foley JE, Gatlin M, Dunn FL, Horton ES. Both nateglinide and metformin sustain HbA(1c) lowering over 52 weeks in drug‐naive type 2 diabetes patients. Diabetologia 2001;44(Suppl 1):826.
Fujita 2001 {published data only}
    1. Fujita T, Kosugi K, Ueda N, Hatano M. Oral nateglinide administration improves glycemic control of Type 2 diabetic patients, treated with intermediate‐acting insulin. Diabetes 2001;50(Suppl 2):A435.
Hasslacher 2001 {published data only}
    1. Hasslacher C, Koselj M, Gall MA, Sieber J, Dieken ML. Safety and efficacy of repaglinide in 281 type 2 diabetic patients with or without renal impairment. Diabetes 2001;50(Suppl 2):A116.
Hatorp 2002 {published data only}
    1. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical Pharmacokinetics 2002;41(7):471‐83. - PubMed
Hirschberg 2000 {published data only}
    1. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23(3):349‐53. - PubMed
Hollander 2001 {published data only}
    1. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet‐treated patients with type 2 diabetes. Diabetes Care 2001;24(6):983‐8. - PubMed
Horton 2001 {published data only}
    1. Horton ES, Gatlin M, Dunn FL, Foley JE. Risks/Benefits of achieving HbA1c goals with nateglinide. Diabetes 2001;50(Suppl 2):A438.
Horton 2003 {published data only}
    1. Horton E, Foley J, Shen S, Baron M. Initial combination therapy with nateglinide and metformin is safe and effective. Diabetes 2003;Suppl 1:A448.
Hoyer 2000 {published data only}
    1. Hoyer M, Mallows S. Nateglinide reduces mean glycemia in diet‐ and previously treated type 2 diabetic patients. Diabetes Research and Clinical Practice 2000;50(Suppl 1):S72.
Ishii 2001 {published data only}
    1. Ishii T, Yamakita T, Yamagami K, Yamamoto T, Miyamoto M, Yoshioka K, et al. Nateglinide is safe and efficacious in lowering postprandial blood glucose in type 2 diabetic patients with various degree of renal function. Diabetes 2001;50(Suppl 2):A118.
Juhl 2000 {published data only}
    1. Juhl CB, Porksen N, Hollingdal M, Sturis J, Pincus S, Veldhuis JD, et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care 2000;23(5):675‐81. - PubMed
Kahn 2001 {published data only}
    1. Kahn SE, Montgomery B, Howell W, Ligueros SM, Hsu CH, Devineni D, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 2001;86(12):5824‐9. - PubMed
Keilson 2000 {published data only}
    1. Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 2000;85(3):1081‐6. - PubMed
Khan 2000 {published data only}
    1. Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying Out or Commissioning Reviews. http://www.york.ac.uk/inst/crd/report4.htm 2000.
Lawrence 2005 {published data only}
    1. Lawrence IG, Srinivasan BT, Tringham J, Jarvis J, Howe J, Skinner C, et al. Insulin treatment after 3 years in patients with type 2 diabetes following participation in a study of combination regimes of insulin, repaglinide and metformin. Diabetes 2005;54(Suppl 1):A513.
Ligueros‐Saylan 2000 {published data only}
    1. Ligueros‐Saylan M, Khalilieh S, Lee J, Devineni D, Sunanda V, Zeig S, et al. Nateglinide has a low hypoglycemic potential in a missed‐meal situation. Diabetes 2000;49:1511.
Mallows 2000 {published data only}
    1. Mallows S, Guitard C. Nateglinide is effective and safe in elderly patients with Type 2 diabetes. Diabetes Research and Clinical Practice 2000;50(Suppl 1):S73.
Merz 2000 {published data only}
    1. Merz M, Walter YH, Brookman L, Ma P, Gerich JE, Mcleod JF. Risk of delayed hypoglycemia is reduced with nateglinide compared to repaglinide. Diabetologia 2000;43(Suppl 1):714.
Mori 2001 {published data only}
    1. Mori Y, Ishii H, Hikita M, Yokoyama J, Tajima N. The improvement of early phase of insulin secretion after glucose load with nateglinide in patients with type 2 diabetes. Diabetes 2001;50(Suppl 2):A127.
Nishimura 2002 {published data only}
    1. Nishimura H, Shintani M, Maeda K, Okuda J, Tanaka S. Multiple effects of Nateglinide on glucose metabolism in obese patients with type 2 diabetes mellitus. Diabetes 2002;51:2528.
Owens 2000a {published data only}
    1. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000;23(4):518‐23. - PubMed
Owens 2000b {published data only}
    1. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000;23(4):518‐23. - PubMed
Rudovich 2002 {published data only}
    1. Rudovich NN, Dieken MHL, Pfeiffer AFH. Comparison of effects of repaglinide and nateglinide on insulin secretion and postloading glucose excursions in patients with Type 2 diabetes. Diabetologia 2002;45:764.
Rudovich 2003 {published data only}
    1. Rudovich N, Rochlitz H, Dieken ML, Pfeiffer A. Comparison of effects of repaglinide and nateglinide on insulin secretion and postloading glucose excursions in patients with type 2 diabetes. Diabetes 2003;52(Suppl 1):A454.
Saad 2002 {published data only}
    1. Saad MF, Hale P, Khutoryansky N. Efficacy of repaglinide vs. nateglinide: As monotherapy or metformin combination therapy. Diabetes 2002;51:536.
Schmitz 2002 {published data only}
    1. Schmitz O, Lund S, Andersen PH, Jonler M, Porksen N. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double‐blind study with repaglinide. Diabetes Care 2002;25(2):342‐6. - PubMed
Schumacher 2001 {published data only}
    1. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, et al. Single‐ and multiple‐dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. European Journal of Clinical Pharmacology 2001;57(2):147‐52. - PubMed
Schwartz 1998 {published data only}
    1. Schwartz SL, Goldberg RB, Strange P. Repaglinide in type 2 diabetes: A randomized, double‐blind, placebo‐controlled, dose‐response study. Diabetes 1998;47(Suppl 1):382.
Srinivasan 2005 {published data only}
    1. Srinivasan BT, Lawrence IG, Tringham J, Jarvis J, Howe J, Skinner C, et al. 3 year follow up of a randomised controlled trial of combination regimes of insulin, repaglinide and metformin in people with type 2 diabetes mellitus. Diabetes 2005;54(Suppl 1):A127.
Strange 1999 {published data only}
    1. Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and dose‐response relationship of repaglinide in type 2 diabetes. Diabetes Technology & Therapeutics 1999;1(3):247‐56. - PubMed
Tankova 2003 {published data only}
    1. Saloranta C, Holmes D, Ball M, Dickinson S, Hershon K. Efficacy and safety of nateglinide in patients with mild hyperglycaemia. Diabetologia 2001;44 Suppl 1:A214. - PubMed
    1. Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Research and Clinical Practice 2003;59(1):43‐9. - PubMed
Torella 2002 {published data only}
    1. Torella R, Lunetta M, Vitali L. Repaglinide plus bedtime insulin is as effective as premixed insulin twice daily but more safe than insulin alone in Type 2 diabetes mellitus inadequately controlled with oha therapy. Diabetologia 2002;45:765.
Walter 2000 {published data only}
    1. Walter YH, Brookman L, Ma P, Gerich JE, Mcleod JF. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide. Diabetes 2000;49(Suppl 1):521.
Wang 2004 {published data only}
    1. Wang FN, Liao ZH, Yao B, Li YB, Hu GL, Weng JP. The impaired acute insulin response in newly diagnosed Type 2 diabetic patients can be restored by nateglinide and repaglinide. Diabetologia 2004;47(Suppl 1):A254.
Whitelaw 2000 {published data only}
    1. Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diabetic Medicine 2000;17(3):225‐9. - PubMed

References to studies awaiting assessment

Brogard 2000 {published data only}
    1. Brogard JM, Landin‐Olsson M, Eriksson J. Repaglinide with bedtime insulin improves glycaemic control in poorly controlled type 2 diabetes. Diabetologia 2000;43:716.
    1. Eriksson JG, Brogard JM, Landin‐Olsson M, Clauson P, Rasmussen M. 1999, 48(Suppl):1575. The safety of repaglinide administered in combination with bedtime NPH‐insulin in patients with type 2 diabetes. A randomized, semi‐blinded, parallel‐group, multi‐centre trial.. Diabetes 1999;48(Suppl):1575.
    1. Landin‐Olsson M, Brogard JMM, Eriksson J, Rasmussen M, Clauson P. A randomized, semi‐blinded, parallel‐group, multi‐centre trial. Diabetes 1999, 48:0503. The efficacy of repaglinide administered in combination with bedtime NPH‐insulin in patients with type 2 diabetes.A randomized, semi‐blinded, parallel‐group, multi‐centre trial.. Diabetes 1999;48:0503.
Davies 2002 {published data only}
    1. Davies MJ, Howe J, Jarvis J, Johnston V, Kitchener D, McNally PG, Lawrence IG. Use of the combination of insulin and the prandinal glucose regulator repaglinide in patients with type 2 diabetes mellitus. Diabetologia 2002;45(Suppl. 2):A265.
    1. Davies MJ, Johnston V, Howe J, Kitchener D, Lawrence IG, McNally PG. Comparison of combination regimes of Insulin, Repaglinide and Metformin in type 2 diabetes: an interim analysis. Diabetic Medicine 2001;18(1 (Suppl.)):A43.
    1. Howe J, Davies MJ, Johnston V, Kitchener D, McNally PG, Lawrence IG. Quality of life and treatment satisfaction with the combination of insulin, metformin and repaglinide in patients with Type 2 diabetes mellitus. Diabetic Medicine 2002;19(Suppl. 2):28‐115.
Li 2005 {published data only}
    1. Li JW, Tian HM, Li QF, Wang NZ, Wu T, Liu Y. Improvement of beta cell function by nateglinide and repaglinide in type 2 diabetic patients: a randomized controlled double blinded and double dummy multicentre study. Diabetologia 2005;48(Suppl. 1):A284. - PubMed
Lund 2005 {published data only}
    1. Lund SS, Tarnow L, Poulsen G, Frandsen M, Smidt U, Pedersen O, Parving HH, Vaag A. Effect of metformin vs repaglinide on postprandial glycaemia, plasma lipoproteins and free fatty acids in non‐obese patients with type‐2 diabetes (T2DM). Diabetologia 2005;48(Suppl. 1):A285.
    1. Lund SS, Tarnow L, Poulsen G, Frandsen M, Smith UM, Pedersen O, Parving HH, Vaag A. Effect of metformin vs. repaglinide on glycaemic control and non‐glycaemic cardiovascular risk‐factors in non‐obese patients with Type 2 diabetes mellitus (T2DM) uncontrolled by diet (The ReMet‐study). Diabetologia 2004;45(Suppl. 1):A252.
Milenkovic 2005 {published data only}
    1. Milenkovic T, Kozar‐Markovic O, Percan V, Vesov G, Mitkova M, Kuzinovska N, Aleksovski B, Makrevska S, Kostojcinoska M, Neceva L, Mat R, Limani E, Kovacevska J. 20‐week multicentre, prospective, open‐label study of the efficacy, safety and applicability of repaglinide as a first line therapy in treating type 2 diabetes patients in Diabetes Centres in Macedonia [Bulgarian]. Endocrinologia 2005;10(1):28‐34.
Panelo 2004 {published data only}
    1. Panelo A, Wing JR. Similar improvement in glycemic control with lower risk of hypoglycemia with repaglinide and bedtime NPH insulin compared to twice dally NPH insulin. Diabetes 2004;53(Suppl. 2):A479.

Additional references

Bastyr 2000
    1. Bastyr EJ, Stuart CA, Brodows RG. Therapy focused on lowering postprandinal glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23:1236‐41. - PubMed
Bonora 2001
    1. Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes. Diabetes Care 2001;24:2023‐2029. - PubMed
Breuer 2000
    1. Breuer HWM. The postprandial blood glucose level. A new traget for optimising treatment of diabetes mellitus. Eur Heart J Supplements 2000;2 (supp D):D36‐D37.
Cohen 1960
    1. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37‐46.
DCCTRG 1993
    1. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus. New England Journal of Medicine 1993;329(14):977‐86. - PubMed
De Fronzo 1999
    1. Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 1999;131(4):281‐303. - PubMed
de Vegt 1999
    1. Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all‐cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. Vol. 42, 1999:926‐31. - PubMed
DECODE 1999
    1. DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnositc criteria. Lancet 1999;354:617‐21. - PubMed
Dornhurst 2001
    1. Dornhurst A. Insulinotrophic meglitinide analogues. Lancet 2001;358:1709‐16. - PubMed
Gerich 2003
    1. Gerich JE. Clinical significance, pathogenesis and management of postprandinal hyperglycaemia. Archives of Internal Medicine 2003;163:1306‐16. - PubMed
Hanefeld 1996
    1. Hanefeld M, Fischer S, Schulze JJ, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11 year follow up. Diabetologia 1996;39:1577‐83. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in medicine 2002;21:1539‐58. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analysis. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Inzucchi 2002
    1. Inzucchi SE. Oral antihyperglycaemic therapy for type 2 diabetes. JAMA 2002;287:360‐72. - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Khan 2000
    1. Khan KS, ter Riet G, Glanville J, Sowden A, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out and commissioning reviews. CRD Report 4 2000; Vol. 2nd edition.
Kirpichnikov 2002
    1. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Annal Internal Medicine 2002;137:25‐33. - PubMed
Landgraf 2000
    1. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs & Ageing 2000;17(5):411‐25. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408‐12. - PubMed
Shiba 2003
    1. Shiba T. Improvement of insulin resistance by a new insulin secretagogue, nateglinide ‐ analysis based on the homeostasis model. Diabetes Research and Clinical Practice 2003;62:87‐94. - PubMed
Stratton 2000
    1. Stratton IM, Adler AI, Neil AW, et al. Association pf glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321:405‐412. - PMC - PubMed
UKPDS 1995
    1. UK Prospective Diabetes Study Group. UK Prospective study 16: overview of 6 years therapy of type II diabetes ‐ a progressive disease. Diabetes 1995;44:1249‐58. - PubMed
Watkins 2003
    1. Watkins PJ. ABC of diabetes: Cardiovascular disease, hypertension, and lipids. BMJ 2003;326:874‐6. - PMC - PubMed
Yudkin 1994
    1. Yudkin JS, Coppack S. Insulin resistance and impaired glucose tolerance. Lancet 1994;344:1294‐5. - PubMed

Publication types

MeSH terms